Central Pancreatectomy: A Center of Debate of Risk versus Benefit
Executive Summary
Central Pancreatectomy (CP) is an organ-preserving surgical technique designed for the segmental resection of benign or low-grade malignant lesions located in the neck and proximal body of the pancreas. While traditional procedures like pancreaticoduodenectomy (PD) and distal pancreatectomy (DP) are oncologically sound, they often result in the sacrifice of significant amounts of healthy pancreatic tissue. CP offers a parenchyma-sparing alternative that significantly reduces the long-term risk of endocrine and exocrine insufficiency.
The primary clinical debate surrounding CP involves the trade-off between functional preservation and immediate post-operative morbidity. While CP is associated with a higher incidence of pancreatic fistulas compared to DP, these complications are typically manageable and rarely lead to mortality. Long-term data indicates that CP patients have a significantly lower risk of developing new-onset diabetes and digestive enzyme deficiencies. Consequently, for appropriately selected patients with non-invasive lesions, the long-term functional benefits of CP are generally considered to outweigh the short-term surgical risks.
Overview and Definitions
Central Pancreatectomy is a parenchyma-sparing operation involving the segmental resection of the mid-portion of the pancreas. It is utilized to preserve the head and the tail of the organ, thereby maintaining physiological function.
Nomenclature
In clinical literature, the procedure is referred to by several synonymous terms:
Middle, Median, or Medial pancreatectomy
Segmental pancreatectomy
Limited conservative pancreatectomy
Intermediate pancreatectomy
Historical Evolution
The development of the procedure spans over a century, evolving from traumatic injury management to elective oncological application:
1908–1910: Initial descriptions of segmental resection provided by Ehrhardt and Finney.
1957: Guillemin and Bessot performed CP for chronic pancreatitis using two pancreaticoenteric anastomoses.
1959: Letton and Wilson utilized the technique for traumatic pancreatic transection.
1984: Dagradi and Serio performed the first CP specifically for a pancreatic neoplasm (a benign insulinoma).
Modern Era: Iacono validated the procedure through functional endocrine and exocrine testing, leading to its worldwide popularization.
Clinical Indications and Patient Selection
The increased use of radiological imaging has led to a rise in the detection of asymptomatic, low-grade pancreatic lesions suitable for CP.
Primary Indications
CP is indicated for lesions in the neck or proximal body that are:
Benign or Low-Grade: Including insulinomas, solid pseudopapillary tumors, serous cystadenomas, and mucinous cystadenomas.
Unsuitable for Enucleation: Lesions in close proximity to the main pancreatic duct or those larger than 2 cm where enucleation might risk inadequate removal or ductal injury.
Solitary Metastasis: Isolated metastatic lesions from other primary tumors.
IPMN: Intraductal Papillary Mucinous Neoplasms (though these carry a slightly higher recurrence risk of approximately 3.3%).
Contraindications
The procedure is strictly contraindicated in several scenarios:
Ductal Adenocarcinoma: CP is oncologically inappropriate for invasive cancer due to limited lymph node dissection and the risk of tumor dissemination if the mass is breached.
Diffuse Disease: Conditions such as diffuse chronic pancreatitis.
Anatomical Constraints: Inability to preserve at least 5 cm of the distal pancreatic stump or the presence of distal body-tail atrophy.
Vascular Limitations: Specific vascular patterns (e.g., Melliere and Moulle type III) where the blood supply to the pancreatic tail is exclusively dependent on arteries located in the resection zone.
Surgical Methodology and Technical Considerations
The procedure requires precise dissection to isolate the central segment from major vascular structures.
Isolation: The pancreas is mobilized at its superior and inferior margins. The posterior surface is dissected from the splenic vein, and collateral vessels from the splenic artery are ligated.
Transection: After placing marginal stitches, the pancreas is transected. Frozen section analysis is mandatory to ensure tumor-free margins.
Proximal Management: The pancreatic duct on the proximal (head) segment is closed via suturing or stapling.
Distal Reconstruction: To maintain drainage of the tail, the distal segment is reconstructed using one of two methods:
Pancreaticojejunostomy (PJ): The most common method (87.6%), involving a Roux-en-Y loop.
Pancreaticogastrostomy (PG): Utilized in 12.4% of cases; some surgeons prefer this as it allows for later endoscopic inspection of the duct.
Laparoscopic Approach
While laparoscopic CP is feasible, it is currently restricted to specialized centers. It is characterized by:
Longer mean operative times (approximately 356 minutes).
A significant pancreatic fistula rate (46%).
No current reduction in mean hospital stay (13.8 days).
Comparative Analysis: Central vs. Distal Pancreatectomy
The clinical utility of CP is best understood when compared to Distal Pancreatectomy (DP), the traditional alternative for mid-body lesions.
Clinical Outcomes and Complications
The Pancreatic Fistula Concern
The primary deterrent for CP is the high rate of pancreatic fistulas, with reported incidences ranging from 0% to 63%.
Causes: The risk is elevated because CP involves two potential leak sites (the closed proximal stump and the distal anastomosis) and is often performed on soft, non-fibrotic pancreases with small-caliber ducts.
Severity: Despite the high frequency, most fistulas are "Grade A" and can be managed conservatively.
Mortality: The perioperative mortality rate remains very low at approximately 0.97%.
Long-Term Functional Benefits
The "real test" of CP is its ability to preserve endocrine and exocrine function.
Endocrine Preservation: Patients undergoing DP have a 9-fold higher risk of developing new-onset diabetes compared to those undergoing CP.
Exocrine Preservation: There is a 3-fold increase in exocrine insufficiency (requiring enzyme substitution) in DP patients compared to CP patients.
Delayed Onset: In cases where deficiencies do occur in CP patients, they take significantly longer to develop than in the DP group.
Local Recurrence Risk
The risk of local recurrence following CP is low, reported at roughly b. This risk is highest in patients with IPMN due to the diffuse nature of the disease. Mitigation strategies include intraoperative pancreaticoscopy and frozen section analysis of the margins.
Conclusion
Central Pancreatectomy is a safe and effective organ-preserving surgical option for benign or low-grade malignant lesions of the pancreatic neck and proximal body. While the procedure carries a higher risk of short-term complications—specifically pancreatic fistulas—these are typically minor and manageable. The significant reduction in long-term metabolic and digestive morbidities (diabetes and exocrine failure) compared to traditional resections confirms that for appropriate clinical indications, the benefits of CP outweigh the surgical risks.
